cagrisema combination semaglutide cagrilintide phase 3 results 2025 Novo Nordisk's outperforms Ozempic in III trial Novo's CagriSema tops semaglutide in
Novo's CagriSema tops semaglutide in ph. 3 diabetes study CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 PMC CagriSema Outperforms Semaglutide Alone Across Phase 3 REIMAGINE Trials HCPLive Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control
Pay in 4 interest-free payments of $6.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




